Grey Power

Grey Wolf Therapeutics is a clinical-stage biotechnology company pioneering a novel approach to treating cancer and autoimmune diseases through antigen modulation. By inhibiting the endoplasmic reticulum aminopeptidases ERAP1 and ERAP2, the company's technology alters the repertoire of neoantigens presented on the cell surface, effectively making tumors visible to the immune system or suppressing self-antigen presentation in autoimmunity. Their lead oncology candidate, GRWD5769, is currently being evaluated in a Phase 1/2 trial for advanced solid tumors. Additionally, the company is advancing GRWD0715 for the treatment of autoimmune conditions. Grey Wolf is backed by a strong syndicate of investors, including Pfizer Ventures and Andera Partners.